References
- Laramore GE, Scott CB, Schuller DE, Haselow RE, Ervin TJ, Wheeler R, et al. Is a surgical resection leaving pos-itive margins of benefit to the patient with locally advanced squamous cell carcinoma of the head and neck: a comparative study using the intergroup study 0034 and the Radiation Therapy Oncology Group head and neck database. Int J Radiat Oncol Biol Phys 1993; 27 (5): 1011–6.
- Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993; 328 (3): 184–94.
- Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350 (19): 1937–44.
- Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350 (19): 1945–52.
- Forastiere AA, Neuberg D, Taylor SGt, DeConti R, Adams G. Phase II evaluation of Taxol in advanced head and neck cancer: an Eastern Cooperative Oncology group trial. J Nati Cancer Inst Monogr 1993; 15: 181–4.
- Fountzilas G, Ciuleanu E, Dafni U, Plataniotis G, Kalogera-Fountzila A, Samantas E, et al. Concomitant Radiochemotherapy vs Radiotherapy Alone in Patients with Head and Neck Cancer: A Hellenic Cooperative Oncology Group Phase III Study. Med Oncol 2004; 21 (2): 95–108.
- Fountzilas G, Athanassiadis A, Samantas E, Skarlos D, Kalogera-Fountzila A, Nikolaou A, et al. Paclitaxel and carbo-platin in recurrent or metastatic head and neck cancer: a phase II study. Semin Oncol 1997; 24 (1 Suppl 2):52-65-52-67.
- Conley B, Jacobs M, Suntharalingam M, Zacharski D, Ord RA, Gray W, et al. A pilot trial of paclitaxel, carboplatin, and concurrent radiotherapy for unresectable squamous cell carcinoma of the head and neck. Semin Oncol 1997; 24 (1 Suppl 2):52-78-52-80.
- Stathopoulos GP, Rigatos S, Papakostas P, Fountzilas G. Effectiveness of paclitaxel and carboplatin combination in heavily pretreated patients with head and neck cancers. Eur J Cancer 1997; 33 (11): 1780–3.
- Hitt R, Paz-Ares L, Hidalgo M, Colomer R, Brandariz A, Pena M, et al. Phase I/II study of paclitaxel/cisplatin as first-line therapy for locally advanced head and neck cancer. Semin Oncol 1997; 24 (6 Suppl 19):519-20-519-24.
- Forastiere AA, Leong T, Rowinsky E, Murphy BA, Vlock DR, DeConti RC, et al. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 2001; 19 (4): 1088–95.
- Shin DM, Glisson BS, Khuri FR, Ginsberg L, Papadimitrakopoulou V, Lee JJ, et al. Phase II trial of pacli-taxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998; 16 (4): 1325–30.
- Suntharalingam M, Haas ML, Conley BA, Egorin MJ, Levy S, Sivasailam S, et al. The use of carboplatin and pacli-taxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 2000; 47 (1): 49–56.
- Wanebo HJ, Chougule P, Ready N, Koness RJ, Akerley W, McRae R, et al. Preoperative paclitaxel, carboplatin, and radiation therapy in advanced head and neck cancer (stage III and IV). Semin Radiat Oncol 1999; 9 (2 Suppl 1):77-84.
- Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal can-cer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991; 324 (24): 1685-90.
- Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radio-therapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349 (22): 2091–8.
- Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 2004; 22 (9): 1743–52.